Selected article for: "cohort study and line combination therapy"
Author: Peri, Anna Maria; Verna, Marta; Biffi, Stefano; Alagna, Laura; Longhi, Benedetta; Migliorino, Guglielmo Marco; Foresti, Sergio; Bandera, Alessandra; Rovelli, Attilio; Rizzari, Carmelo; Gori, Andrea; Colombini, Antonella
Title: Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
  • Document date: 2019_9_5
    • ID: 1egushdn_32
    Snippet: In a recent Italian multicenter study on 127 invasive fungal infections in hemato-oncological pediatric patients, up to 45/126 (36%) episodes were treated with antifungal combinations as initial therapy and the author speculates that this choice was driven by the more severe clinical conditions of these patients [19] . Furthermore, in the international multicenter observational cohort study by Wattier et al on 131 IMI in children affected by hema.....
    Document: In a recent Italian multicenter study on 127 invasive fungal infections in hemato-oncological pediatric patients, up to 45/126 (36%) episodes were treated with antifungal combinations as initial therapy and the author speculates that this choice was driven by the more severe clinical conditions of these patients [19] . Furthermore, in the international multicenter observational cohort study by Wattier et al on 131 IMI in children affected by hematological neoplasms, first-line combination therapy was used in 53% of cases and, similar to our findings, it was mainly used in patients who were already receiving anti-mold prophylaxis possibly due to concerns about prophylaxis-induced resistance [5] .

    Search related documents:
    Co phrase search for related documents
    • antifungal combination and cohort study: 1, 2
    • antifungal combination and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • antifungal combination and fungal infection: 1, 2
    • antifungal combination and line combination therapy: 1
    • antifungal combination and multicenter study: 1
    • clinical condition and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical condition and combination therapy: 1, 2, 3, 4
    • clinical condition and fungal infection: 1
    • clinical condition and initial therapy: 1
    • clinical condition and multicenter study: 1, 2, 3, 4, 5, 6
    • clinical condition and patient clinical condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical condition and pediatric patient: 1, 2
    • cohort study and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cohort study and fungal infection: 1, 2, 3, 4, 5, 6, 7
    • cohort study and initial therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • cohort study and line combination therapy: 1
    • cohort study and multicenter study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cohort study and pediatric patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • combination therapy and multicenter study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15